Juno Therapeutics Inc (NASDAQ:JUNO) saw unusually-strong trading volume on Thursday . Approximately 4,202,753 shares were traded during mid-day trading, an increase of 17% from the previous session’s volume of 3,606,584 shares.The stock last traded at $29.14 and had previously closed at $30.42.

JUNO has been the subject of several research reports. Morgan Stanley raised their price target on shares of Juno Therapeutics from $48.00 to $50.00 in a report on Friday, April 8th. Vetr cut shares of Juno Therapeutics from a “strong-buy” rating to a “buy” rating and set a $53.00 price target for the company. in a report on Monday, June 6th. Maxim Group restated a “buy” rating and set a $80.00 price target (up from $78.00) on shares of Juno Therapeutics in a report on Monday, April 11th. FBR & Co restated a “buy” rating and set a $73.00 price target on shares of Juno Therapeutics in a report on Saturday, April 9th. Finally, SunTrust Banks Inc. restated a “buy” rating and set a $50.00 price target on shares of Juno Therapeutics in a report on Sunday, March 20th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $53.11.

The stock’s market capitalization is $2.91 billion. The firm has a 50 day moving average price of $40.37 and a 200 day moving average price of $38.13.

Juno Therapeutics (NASDAQ:JUNO) last posted its earnings results on Monday, May 9th. The biopharmaceutical company reported ($0.78) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.52) by $0.26. The company earned $9.80 million during the quarter, compared to analyst estimates of $4.83 million. During the same period last year, the firm posted ($0.30) earnings per share. On average, equities analysts anticipate that Juno Therapeutics Inc will post ($2.28) EPS for the current fiscal year.

In related news, EVP Hyam Levitsky sold 12,418 shares of the stock in a transaction that occurred on Friday, June 17th. The stock was sold at an average price of $42.77, for a total transaction of $531,117.86. Following the completion of the sale, the executive vice president now directly owns 117,000 shares of the company’s stock, valued at approximately $5,004,090. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Richard Klausner sold 12,000 shares of the stock in a transaction that occurred on Friday, June 24th. The stock was sold at an average price of $40.71, for a total value of $488,520.00. Following the sale, the director now directly owns 846,799 shares of the company’s stock, valued at $34,473,187.29. The disclosure for this sale can be found here.

A number of hedge funds have bought and sold shares of the company. US Bancorp DE boosted its stake in Juno Therapeutics by 1.8% in the fourth quarter. US Bancorp DE now owns 88,700 shares of the biopharmaceutical company’s stock worth $3,900,000 after buying an additional 1,600 shares during the last quarter. BNP Paribas Arbitrage SA boosted its position in shares of Juno Therapeutics by 27.0% in the fourth quarter. BNP Paribas Arbitrage SA now owns 51,206 shares of the biopharmaceutical company’s stock valued at $2,252,000 after buying an additional 10,884 shares in the last quarter. BBR Partners LLC acquired a new position in shares of Juno Therapeutics during the fourth quarter valued at $1,539,000. Stevens Capital Management LP acquired a new position in shares of Juno Therapeutics during the fourth quarter valued at $2,315,000. Finally, Swiss National Bank acquired a new position in shares of Juno Therapeutics during the fourth quarter valued at $2,603,000.

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Juno’s product candidates, JCAR015, JCAR017 and JCAR014, utilize CAR technology to target CD19, a protein expressed on the surface of various B cell leukemias and lymphomas.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.